MSDC-0160(Mitoglitazone CAY-10415)

Molecular Weight (MW)	370.42
Formula	C19H18N2O4S
CAS No.	146062-49-9
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
SMILES	O=C(N1)SC(CC2=CC=C(OCC(C3=NC=C(CC)C=C3)=O)C=C2)C1=O
Synonyms	Mitoglitazone; CAY10415; MSDC 0160; CAY 10415; MSDC-0160; CAY-10415; CAY 10415; CAY-10415; MSDC0160; CAY10415;

Molecular Weight (MW)

370.42

Formula

C19H18N2O4S

CAS No.

146062-49-9

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: <1 mg/mL

Water: <1 mg/mL

Ethanol: <1 mg/mL

SMILES

O=C(N1)SC(CC2=CC=C(OCC(C3=NC=C(CC)C=C3)=O)C=C2)C1=O

Synonyms

Mitoglitazone; CAY10415; MSDC 0160; CAY 10415; MSDC-0160; CAY-10415; CAY 10415; CAY-10415; MSDC0160; CAY10415;

In Vitro	In vitro activity: MSDC-0160 reduces resistance in the insulin/IGF-1 signaling pathway and restores IGF-1-induced Akt and GSK-3 phosphorylation. MSDC-0160 in combination with IGF-1 and 8 mM glucose increases β-cell specific gene expression of insulin, pdx1, nkx6.1, and nkx2.2, and maintains insulin content without altering glucose-stimulated insulin secretion. Furthermore, MSDC-0160 promotes human β-cell differentiation and reduces the expression of markers of apoptosis. Kinase Assay: MSDC-0160 at 50μM alone also prevents the loss of insulin content significantly. Besides that, treatment of MSDC-0160 increases the phosphorylation of AMPK and reduces mTOR phosphorylation. Moreover, MSDC-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2. Cell Assay: MSDC-0160 exerts prevention of nuclear translocation with β-catenin localized on the cell membrane or cytoplasm in human β-cells
In Vivo	MSDC-0160 (100 mg/kg p.o.) improves insulin sensitivity by resulting in the large decrease in the product of circulating insulin and glucose in diabetic KKAy mice.
Animal model	Diabetic KKAy mice
Formulation & Dosage	Suspended in 1% sodium methyl carboxycellulose/0.01% Tween 20; 100 mg/kg; p.o.
References	PLoS One. 2013 May 1;8(5):e62012; Gene Regul Syst Bio. 2007 Sep 17;1:73-82.

In Vitro

In vitro activity: MSDC-0160 reduces resistance in the insulin/IGF-1 signaling pathway and restores IGF-1-induced Akt and GSK-3 phosphorylation. MSDC-0160 in combination with IGF-1 and 8 mM glucose increases β-cell specific gene expression of insulin, pdx1, nkx6.1, and nkx2.2, and maintains insulin content without altering glucose-stimulated insulin secretion. Furthermore, MSDC-0160 promotes human β-cell differentiation and reduces the expression of markers of apoptosis.

Kinase Assay: MSDC-0160 at 50μM alone also prevents the loss of insulin content significantly. Besides that, treatment of MSDC-0160 increases the phosphorylation of AMPK and reduces mTOR phosphorylation. Moreover, MSDC-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2.

Cell Assay: MSDC-0160 exerts prevention of nuclear translocation with β-catenin localized on the cell membrane or cytoplasm in human β-cells

In Vivo

MSDC-0160 (100 mg/kg p.o.) improves insulin sensitivity by resulting in the large decrease in the product of circulating insulin and glucose in diabetic KKAy mice.

Animal model

Diabetic KKAy mice

Formulation & Dosage

Suspended in 1% sodium methyl carboxycellulose/0.01% Tween 20; 100 mg/kg; p.o.

References

PLoS One. 2013 May 1;8(5):e62012; Gene Regul Syst Bio. 2007 Sep 17;1:73-82.

CAS NO:	146062-49-9
规格:	≥98%

包装	价格(元)
1mg	电议
2mg	电议
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议
250mg	电议
500mg	电议